<PAGE>
SECURITIES EXCHANGE AND COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
JUNE 12, 1997
Date of Report (DATE OF EARLIEST EVENT REPORTED)
COCENSYS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of incorporation)
0-20954 33-0538836
(Commission File Number) (IRS Employer Identification No.)
213 TECHNOLOGY DRIVE
IRVINE, CALIFORNIA 92718
(Address of principal executive offices and zip code)
(714) 753-6100
(Registrant's telephone number, including area code)
<PAGE>
Item 5. OTHER EVENTS.
On June 12, 1997, CoCensys, Inc. (the "Company") announced that the
Company and the Parke-Davis Division of Warner-Lambert Company have agreed to
terminate the Cognex Promotion Agreement.
Item 7. EXHIBITS.
99.1 Press Release, titled "CoCensys, Parke-Davis Negotiating New
Co-promotion Agreement; Cognex Promotion Terminated," dated
June 12, 1997.
2.
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
COCENSYS, INC.
Dated: June 17, 1997 By: /s/ Peter E. Jansen
----------------------------------
Peter E. Jansen
Vice President and Chief
Financial Officer
3.
<PAGE>
INDEX TO EXHIBITS
EXHIBIT SEQUENTIALLY
NUMBER DESCRIPTION NUMBERED PAGE
99.1 Press Release, titled "CoCensys, Parke-Davis
Negotiating New Co-promotion Agreement; 5
Cognex Promotion Terminated," dated June 12, 1997.
<PAGE>
Exhibit 99.1
Contact: Rick Henson Christi Foster
President Communications Director
Pharmaceutical Sales & Marketing Division (714) 753-6112
(714) 753-6100
FOR IMMEDIATE RELEASE
COCENSYS, PARKE-DAVIS NEGOTIATING NEW CO-PROMOTION AGREEMENT
COGNEX PROMOTION TERMINATED
IRVINE, California/PR Newswire/June 12, 1997 -- CoCensys, Inc. (Nasdaq: COCN)
announced today that, effective immediately, the Parke-Davis Division of
Warner-Lambert Company will phase out active detailing, marketing and patient
support programs for its Alzheimer's drug, Cognex-Registered Trademark-. In
line with this decision, CoCensys and Parke-Davis have agreed to terminate
the contract for detailing the drug to U.S. neurologists.
"Cognex-Registered Trademark- helped establish a standard by which future
Alzheimer's compounds may be measured," said Wayne Dickerson, Director of New
Business Ventures for Warner-Lambert. "Cognex-Registered Trademark- has been
an important milestone in the treatment of Alzheimer's disease, and our
partnership with CoCensys has been an integral part of bringing the treatment
to patients. We look forward to continuing our relationship with CoCensys on
future projects." He noted that Cognex-Registered Trademark- remains a
viable treatment option and will continue to be made available by Parke-Davis.
"CoCensys is currently in late-stage negotiations with Parke-Davis on a
replacement product," said Rick Henson, President of the Pharmaceutical Sales
and Marketing Division. "We also continue to explore other co-promotion or
in-licensing opportunities and are working diligently to bring promising new
drugs into our portfolio."
The forward-looking statements contained above involve a high degree of
technological, regulatory and competitive risks and uncertainties inherent to
biopharmaceutical companies. Actual results may differ due to a number of
factors, including risks inherent to collaboration negotiations and others
that are more fully discussed in the company's most recent Form 10-K and Form
10-Q.
CoCensys is a biopharmaceutical company that discovers, develops and markets
products to treat neurological and psychiatric disorders. The company's
product development programs focus on three proprietary technology platforms
for the treatment of migraine, epilepsy, anxiety, insomnia, stroke, head
trauma and neurodegenerative diseases. CoCensys' Pharmaceutical Sales and
Marketing Division markets Somerset Pharmaceuticals' Eldepryl-Registered
Trademark- for Parkinson's disease to neurologists. More information about
the company is available on its website: http://www.cocensys.com.
###
